Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury
NCT ID: NCT06107556
Last Updated: 2023-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2023-10-19
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of an Eccentric Muscle Strengthening Protocol on Force Moment, Muscle Activation and Plantar Flexor Structure of Patients With Central Nervous System Injuries.
NCT06099340
Training of Eccentric Lower Extremity Function After SCI
NCT02498548
Eccentric Motor Control After SCI
NCT02821845
Biomechanical Characterization of the Locomotion in Multiple Sclerosis Patients
NCT03756142
Effects of Continuous Passive Motion on the Spinal Circuitries and Its Adaptation in Patients With Spasticity Resulting From Upper Motor Neuron Lesions
NCT02122276
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gait analysis
3D gait analysis with electromyographic measurements
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Person who performed tridimensional gait analysis in laboratory
* Person who had a stroke at least 6 months before the gait analysis
Exclusion Criteria
* Botulinum toxin injection in the last 3 months before the gait analysis
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henri Mondor University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emilie Hutin
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emilie Hutin
Role: PRINCIPAL_INVESTIGATOR
Hôpitaux Universitaires Henri Mondor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Laboratoire Analyse et Restauration du Mouvement
Créteil, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-A02258-37
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.